Does rosuvastatin lower blood pressure
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
The Impact of Rosuvastatin on Blood Pressure: A Comprehensive Review
Introduction to Rosuvastatin and Blood Pressure
Rosuvastatin, a statin primarily used to lower cholesterol, has been investigated for its potential effects on blood pressure (BP). This article synthesizes findings from multiple studies to determine whether rosuvastatin can effectively lower BP in patients with hypertension and dyslipidemia.
Rosuvastatin and Diastolic Blood Pressure (DBP)
Several studies have demonstrated that rosuvastatin can significantly reduce diastolic blood pressure (DBP). A meta-analysis of randomized controlled trials (RCTs) found that rosuvastatin treatment resulted in a modest but significant reduction in DBP by an average of 2.12 mmHg compared to non-rosuvastatin treatments. This finding is supported by another study that observed a significant decrease in DBP in patients treated with rosuvastatin, indicating its potential benefit in managing hypertension.
Rosuvastatin and Systolic Blood Pressure (SBP)
The effects of rosuvastatin on systolic blood pressure (SBP) are less conclusive. The same meta-analysis mentioned above noted a trend towards lowered SBP with rosuvastatin treatment, but the reduction was not statistically significant. However, other studies have shown more promising results. For instance, a study involving a fixed-dose combination of rosuvastatin and candesartan reported significant reductions in SBP, suggesting that rosuvastatin may have a more pronounced effect when used in combination with other antihypertensive agents.
Mechanisms of Action: Nitric Oxide and Endothelial Function
Rosuvastatin's potential to lower BP may be linked to its effects on nitric oxide (NO) and endothelial function. Research on mice has shown that rosuvastatin can improve NO-dependent heart rate and BP variability by decreasing caveolin-1 expression, an inhibitor of endothelial NO synthase. This improvement in endothelial function could contribute to the observed reductions in BP.
Combination Therapies and Central Blood Pressure
Combination therapies involving rosuvastatin have shown enhanced BP-lowering effects. A study comparing a single-pill combination of telmisartan and rosuvastatin with telmisartan monotherapy found that the combination therapy significantly reduced central SBP, which is a critical factor in cardiovascular risk. Similarly, a combination of rosuvastatin and amlodipine was more effective in reducing both SBP and DBP compared to monotherapies.
Long-Term Cardiovascular Benefits
Long-term studies have highlighted the cardiovascular benefits of rosuvastatin beyond BP reduction. The Heart Outcomes Evaluation Prevention (HOPE)-3 study demonstrated that rosuvastatin significantly reduced major adverse cardiovascular events (MACE) over an extended follow-up period, particularly in participants with elevated SBP. This suggests that rosuvastatin's benefits in cardiovascular health may extend beyond its lipid-lowering properties.
Conclusion
In summary, rosuvastatin has been shown to modestly reduce DBP and potentially lower SBP, especially when used in combination with other antihypertensive agents. Its beneficial effects on endothelial function and long-term cardiovascular outcomes further support its use in patients with hypertension and dyslipidemia. While the evidence is promising, more research is needed to fully understand the extent of rosuvastatin's BP-lowering capabilities.
Sources and full results
Most relevant research papers on this topic